Northland Securities upgraded Endo International plc – Ordinary Shares (NASDAQ:ENDP) to Outperform in a statement released earlier today.
- Updated: September 29, 2016
Northland Securities has upgraded Endo International plc – Ordinary Shares (NASDAQ:ENDP) to Outperform in a report released on Thursday September 29, 2016.
On Friday September 16, 2016, Citigroup released a statement on Endo International plc – Ordinary Shares (NASDAQ:ENDP) reduced the target price from $40.00 to $25.00. At the time, this suggested an upside of 0.22%.
Displaying a price of $21.91, Endo International plc – Ordinary Shares (NASDAQ:ENDP) traded -1.35% lower on the day. With the last close up 3.64% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ENDP has recorded a 50-day moving average of $21.51 and a two hundred day average of $21.29. Volume of trade was down over the average, with 1,606,023 shares of ENDP changing hands under the typical 6,900,490
See Chart Below
Endo International plc – Ordinary Shares has a with a 52 week low of $12.56 and a one year high of $72.85 ENDP’s market capitalization is currently $0.
Also covering Endo International plc – Ordinary Shares's price target, a total of 19 analysts have issued a ratings update on the company. The average stock price target is $30.05 with 3 brokers rating the stock a strong buy, five equity analysts rating the company a buy, thirteen analysts rating the company a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell.
More About Endo International plc – Ordinary Shares (NASDAQ:ENDP)
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain management products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, as well as XIAFLEX for treating PeyronieÂ’s and DupuytrenÂ’s contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, as well as Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The companyÂ’s U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides Monarc subfascial hammock to treat female stress urinary incontinence; and Elevate transvaginal pelvic floor repair system for the treatment of pelvic organ prolapse. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.